Hormone replacement therapy: relation to homocysteine and prooxidant-antioxidant status in healthy postmenopausal women

Arch Gynecol Obstet. 2012 Mar;285(3):733-9. doi: 10.1007/s00404-011-2051-2. Epub 2011 Aug 30.

Abstract

Objectives: Studies have consistently shown a lower cardiovascular risk in women who received postmenopausal hormone replacement therapy (HRT).

Design and methods: In this study, the effects of HRT were investigated on plasma total homocysteine (tHcy) and the oxidant-antioxidant status in postmenopausal women. 35 of postmenopausal receiving (2 mg estrodiol valerate + 1 mg cyproterone acetate) HRT group, the remaining 25 received orally placebo (NHRT group).

Results: There was no significant change in plasma tHcy levels between HRT and NHRT groups. Malondialdehyde (MDA) and total thiol (t-SH) correlated significantly with tHcy (0.388 and 0.478, respectively) content, and there was a significant negative correlation between E2 level and glutathione transferase (GST) activity (-0.425) in HRT group. Superoxide dismutase (SOD) and HDL-C correlated significantly with t-SH level (0.339 and 0.336, respectively) in plasma after HRT.

Conclusion: Our results show that HRT is beneficial in the protection against oxidative damage, and prevents atherosclerotic complications.

MeSH terms

  • Adult
  • Cyproterone Acetate / therapeutic use*
  • Estradiol / analogs & derivatives*
  • Estradiol / blood
  • Estradiol / therapeutic use
  • Estrogen Replacement Therapy*
  • Female
  • Glutathione Transferase / blood
  • Homocysteine / blood*
  • Humans
  • Malondialdehyde / blood
  • Middle Aged
  • Oxidative Stress / drug effects
  • Postmenopause / blood
  • Sulfhydryl Compounds / blood
  • Superoxide Dismutase / blood

Substances

  • Sulfhydryl Compounds
  • Homocysteine
  • Cyproterone Acetate
  • Estradiol
  • Malondialdehyde
  • Superoxide Dismutase
  • Glutathione Transferase